Interleukin 1 and 2 production in homosexual men: A controlled trial of therafectin (SM-1213), a possible immunomodulator

Joanne M. Goldsmith*, Jay Huprikar, Samuel J.Y. Wu, John Phillip Phair

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

5 Scopus citations

Abstract

Patients with the acquired immunodeficiency syndrome (AIDS) are susceptible to a variety of opportunistic pathogens which require intact cellular immunity for control and eradication. We evaluated interleukin 1 and 2 production in 12 homosexual men without AIDS but with evidence of altered cell-mediated immunity and serologic evidence of infection with human T-cell lymphotrophic virus type III (HTLV-III). the etiologic agent of AIDS and found production of both factors diminished compared to heterosexual controls. Therafectin (SM-1213) is a new agent which selectively activates macrophages and stimulated interleukin 1 production in vitro. Therafectin was administered to these same 12 patients in a double-blind, placebo controlled trial. We failed to find any significant changes in their immunologic status including interleukin 1 or 2 production.

Original languageEnglish (US)
Pages (from-to)1-14
Number of pages14
JournalJournal of Immunopharmacology
Volume8
Issue number1
DOIs
StatePublished - Jan 1 1986

ASJC Scopus subject areas

  • Immunology and Allergy
  • Immunology
  • Toxicology
  • Pharmacology

Fingerprint Dive into the research topics of 'Interleukin 1 and 2 production in homosexual men: A controlled trial of therafectin (SM-1213), a possible immunomodulator'. Together they form a unique fingerprint.

Cite this